Loading...

2,281 posters, 63 videos, 56 audios, 43 topics, 18 sessions, 6,174 authors, 2,323 institutions

ePostersLive by SciGen Technologies S.A. All rights reserved.

RCOG World Congress 2025

June 23 - 25, 2025 | ExCeL London, UK

EP.1004

The performance of ASPRE based screening in routine clinical practice.

Part of Topic

High risk pregnancy

The performance of ASPRE based screening in routine clinical practice.

Teddy Golob and Ramesh Ganapathy – Epsom and St Helier NHS trust, London UK. 

 


Objective: 

UK national guidelines from the National Institute of Clinical Care Excellence(NICE) recommend screening for preeclampsia (PE) based on maternal characteristics [1]. There is evidence that such screening has a poor detection rate [2]. The FetalMedicine Foundation (FMF) has proposed a model for screening at 11-13 weeks that includes maternal blood pressure, uterine artery Doppler and  placental growth factor (PLGF) [3]. The objective of our study was to compare the effectiveness of combined screening for PE using the FMF algorithm compared to a maternal-factor based model (NICE). 

 

Design:

This was a retrospective cohort study from January2022 to April 2024. The inclusion criteria was women who consented to screening for PE at 11-13 weeks’ gestation with a viable singleton pregnancy. We excluded multiple pregnancies, fetalabnormalities, miscarriages, terminations and those with incomplete outcome data. PE was defined by ISSHP [4] definition and was divided into early (<34 weeks), preterm (<37 weeks) and term (≥37 weeks’). Detectionrates (DR) and screen positive rates (SPR) were compared between the FMF and NICE models. The study was approved by NHS Health research authority (no. 326047).   

 

Design:

This was a retrospective cohort study from January2022 to April 2024. The inclusion criteria was women who consented to screening for PE at 11-13 weeks’ gestation with a viable singleton pregnancy. We excluded multiple pregnancies, fetalabnormalities, miscarriages, terminations and those with incomplete outcome data. PE was defined by ISSHP [4] definition and was divided into early (<34 weeks), preterm (<37 weeks) and term (≥37 weeks’). Detectionrates (DR) and screen positive rates (SPR) were compared between the FMF and NICE models. The study was approved by NHS Health research authority (no. 326047).   

 

Conclusion:

The FMF algorithm was more accurate at predicting early PE and preterm PE but was not significantly different in its prediction of term PE.  

References:

1.Hypertension in pregnancy: diagnosis and management. 2023. NICE
2.Tan et al. Protocol for the prospective validation study: ‘Screening programme for pre‐eclampsia’ (SPREE). 2017.
3.Akolekar R et al. Competing Risks Model in Early Screening for Preeclampsia by Biophysical and Biochemical Markers. 2013.
4.Brown M et al. The hypertensive disorders of pregnancy: ISSHP classification, diagnosis & management recommendations for international practice. 2018.


Copyright © 2015-2026, ePostersLive® SciGen is a registered trademark of SciGen Technologies S.A. Patent pending.

This website and third-party tools we use rely on cookies for the best user experience. By selecting "I agree", you agree to cookie usage as described in our Privacy Policy.